Literatur
- 1
Grundy S M, Hansen B, Smith S C et al.
Clinical management of metabolic syndrome. Report of the American Heart Association / National
Heart, Lung, and Blood Institute / American Diabetes Association Conference on scientific
issues related to management.
Circulation.
2004;
109
551-556
- 2
Taskinen M R.
Diabetic dyslipidaemia: from basic research to clinical practice.
Diabetologia.
2003;
46
733-749
- 3
Austin M A, King M C, Vranizan K M et al.
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease
risk.
Circulation.
1990;
82
495-506
- 4
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) .
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III) final report.
Circulation.
2002;
106
3143-3421
, (Risikokalkulator: www.chd-taskforce.com)
- 5
Grundy S M, Cleeman J I, Merz C N et al.
Coordinating Committee of the National Cholesterol Education Program. Implications
of recent clinical trials for the National Cholesterol Education Program Adult Treatment
Panel III guidelines.
Arterioscler Thromb Vasc Biol.
2004;
24
e149-e161
- 6
American Diabetes Association .
Standards of medical care in diabetes. Position Statement.
Diabetes Care.
2005;
28 (Suppl 1)
4-37
- 7
Deutsche Diabetes-Gesellschaft .
Praxisleitlinien der Deutschen Diabetes-Gesellschaft.
Diabetes und Stoffwechsel.
2002;
11
3-4
- 8
Parhofer K G, Laubach E, Geiß H C et al.
Effect of glucose control on lipid levels in patients with type 2 diabetes.
Deutsche Med Wochenschr.
2002;
127
958-962
- 9
Parhofer K G, Otto C, Geiss H C et al.
Effect of Pioglitazone on lipids in well controlled patients with diabetes mellitus
type 2 – results of a pilot study.
Exp Clin Endocrinol Diabetes.
2005;
113
49-52
- 10
Parhofer K G, Birkeland K I, DeFronzo R et al.
Irbesartan has no short-term effect on insulin resistance in hypertensive patients
with additional cardiometabolic risk factors (i-RESPOND).
Int J Clin Pract.
2010;
64
160-168
- 11
Baigent C, Keech A, Kearney P M for the Cholesterol Treatment Trialists (CTT) Collaborators.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis
of data from 90 056 participants in 14 randomised trials of statins.
Lancet.
2005;
366
1267-1278
- 12
Frost R J, Otto C, Geiss H C et al.
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein
subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus
with mixed hyperlipoproteinemia.
Am J Cardiol.
2001;
87
44-48
- 13
Geiss H C, Dietlein M, Parhofer K G.
Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.
Exp Clin Endocrinol Diabetes.
2003;
111
322-324
- 14
Keech A, Simes R J, Barter P FIELD study investigators et al.
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with
type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Lancet.
2005;
366
1849-1861
- 15
Taylor A J, Sullenberger L E, Lee H J et al.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol
(ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on
atherosclerosis progression in secondary prevention patients treated with statins.
Circulation.
2004;
110
3512-3517
- 16
Taylor A J, Villines T C, Stanek E J et al.
Extended-release niacin or Ezetimibe and carotid intima-media thickness.
N Engl J Med.
2009;
361
2113-2122
Prof. Dr. K. G. Parhofer
Klinikum der Universität München – Großhadern · Medizinische Klinik II
Marchioninistraße 15
81377 München
Email: Klaus.Parhofer@med.uni-muenchen.de
